MCIM
KALV

Meadow Creek Investment Management’s KalVista Pharmaceuticals KALV Stock Holding History

Meadow Creek Investment Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$7K Hold
608
– – ﹤0.01% 1358
2019
Q2 		$13K Hold
608
– – ﹤0.01% 1338
2019
Q1 		$17K Hold
608
– – ﹤0.01% 1320
2018
Q4 		$12K Buy
+608
New +$12.2K ﹤0.01% 1295

Other funds holding KALV

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Meadow Creek Investment Management's KALV Position: Q3 2019 in Review

Meadow Creek Investment Management held its KalVista Pharmaceuticals (KALV) position steady in Q3 2019 at 608 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #1358.

Meadow Creek Investment Management first reported a position in KALV in Q4 2018 and has held it in 4 quarters since. The position peaked at $17K in Q1 2019. 76 funds tracked by Wall St. Rank hold KALV as of Q3 2019.

  • Meadow Creek Investment Management held 608 shares of KalVista Pharmaceuticals worth $7K as of Q3 2019.
  • Meadow Creek Investment Management left its KalVista Pharmaceuticals share count unchanged in Q3 2019.
  • KalVista Pharmaceuticals made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #1358 holding.
  • Meadow Creek Investment Management first reported a position in KalVista Pharmaceuticals in Q4 2018 and has held it in 4 quarters since.
  • Meadow Creek Investment Management's KalVista Pharmaceuticals position peaked at $17K in Q1 2019.
  • 76 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.